Vol. 5 No. 9 (2025)
Reimbursement Reviews

Antihemophilic Factor VIII (Recombinant, B-Domain Deleted), Fc-VWF-XTEN Fusion Protein (Altuviiio)

Published September 17, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Altuviiio; strength: 250 IU, 500 IU, 1,000 IU, 2,000 IU, 3,000 IU, and 4,000 IU vials; formulation: lyophilized powder for reconstitution; route of administration: IV use after reconstitution.
  • Indication: In adults, adolescents, and children with hemophilia A (congenital factor VIII [FVIII] deficiency) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes, treatment and control of bleeding episodes, and perioperative management of bleeding (surgical prophylaxis).